Literature DB >> 31073477

Innovative Strategies for the Management of a Massive Neonatal Rhabdomyoma.

N Prabhu1, N Osifodunrin2, D Murphy2, S Butler3, L E Hunter1.   

Abstract

Rhabdomyomas are histologically benign tumors known to be associated with tuberous sclerosis. The natural history predicts the majority of tumors to be asymptomatic and regress within the first year of life. We describe a neonate presenting on day 1 of life with cardiovascular collapse secondary to a massive rhabdomyoma. Surgical resection was excluded due to the extensive nature of the lesion and oral sirolimus, a mammalian target of rapamycin inhibitor, was commenced to promote tumor regression. The patient developed intractable arrhythmias requiring extracorporeal life support during therapy.

Entities:  

Keywords:  extracorporeal life support; mTOR inhibitors; rhabdomyoma

Year:  2017        PMID: 31073477      PMCID: PMC6260344          DOI: 10.1055/s-0037-1606574

Source DB:  PubMed          Journal:  J Pediatr Intensive Care        ISSN: 2146-4626


  15 in total

1.  Natural history of cardiac rhabdomyoma in infancy and childhood.

Authors:  J F Smythe; J D Dyck; J F Smallhorn; R M Freedom
Journal:  Am J Cardiol       Date:  1990-11-15       Impact factor: 2.778

Review 2.  Upstream and downstream of mTOR.

Authors:  Nissim Hay; Nahum Sonenberg
Journal:  Genes Dev       Date:  2004-08-15       Impact factor: 11.361

3.  Images in cardiovascular medicine. Neonatal tuberous sclerosis and multiple cardiac arrhythmias.

Authors:  Yaniv Bar-Cohen; Michael J Silka; Mark S Sklansky
Journal:  Circulation       Date:  2007-04-17       Impact factor: 29.690

4.  Cardiac tumors and associated arrhythmias in pediatric patients, with observations on surgical therapy for ventricular tachycardia.

Authors:  Christina Y Miyake; Pedro J Del Nido; Mark E Alexander; Frank Cecchin; Charles I Berul; John K Triedman; Tal Geva; Edward P Walsh
Journal:  J Am Coll Cardiol       Date:  2011-10-25       Impact factor: 24.094

5.  Everolimus: a challenging drug in the treatment of multifocal inoperable cardiac rhabdomyoma.

Authors:  Haci Ahmet Demir; Filiz Ekici; Arzu Yazal Erdem; Suna Emir; Bahattin Tunç
Journal:  Pediatrics       Date:  2012-06-25       Impact factor: 7.124

6.  Rapid regression of left ventricular outflow tract rhabdomyoma after sirolimus therapy.

Authors:  Colm Breathnach; Jane Pears; Orla Franklin; David Webb; Colin J McMahon
Journal:  Pediatrics       Date:  2014-09-01       Impact factor: 7.124

7.  Regression of a cardiac rhabdomyoma in a patient receiving everolimus.

Authors:  Dana Tiberio; David N Franz; John R Phillips
Journal:  Pediatrics       Date:  2011-04-04       Impact factor: 7.124

8.  Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome.

Authors:  Samer Kaylani; Amy J Theos; Joseph G Pressey
Journal:  Pediatr Dermatol       Date:  2013-01-15       Impact factor: 1.588

Review 9.  Outcome of antenatally diagnosed cardiac rhabdomyoma: case series and a meta-analysis.

Authors:  A S Chao; A Chao; T H Wang; Y C Chang; Y L Chang; C C Hsieh; R Lien; W J Su
Journal:  Ultrasound Obstet Gynecol       Date:  2008-03       Impact factor: 7.299

Review 10.  Is mTOR inhibition a systemic treatment for tuberous sclerosis?

Authors:  Romina Moavero; Antonella Coniglio; Francesco Garaci; Paolo Curatolo
Journal:  Ital J Pediatr       Date:  2013-09-17       Impact factor: 2.638

View more
  1 in total

Review 1.  Treatment of Cardiac Rhabdomyomas with mTOR Inhibitors in Children with Tuberous Sclerosis Complex-A Systematic Review.

Authors:  Monika Sugalska; Anna Tomik; Sergiusz Jóźwiak; Bożena Werner
Journal:  Int J Environ Res Public Health       Date:  2021-05-05       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.